Drugs / SPRX002
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05457010 | Nov 2022 → Sep 2025 | acute myeloid leukemia, myelodysplastic syndrome | Arcellx, Inc. | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SPRX002 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05457010 ↗ |
| Modality | Protein / enzyme biologic | “SPRX002 is a soluble protein” NCT05457010 ↗ |